PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy (IMMUNOPET2)

Regional University Hospital Center (CHRU)

Status: Enrolling

Conditions: Metastatic Melanoma

Treatments: Diagnostic Test: value of 4D body-to-whole dynamic acquisition in FDG

Study type: Observational

Funder types: Other

Identifiers

NCT04272658

29BRC19.0194 (IMMUNO-PET2)

Details and patient eligibility

About

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

Enrollment: 56 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient old ≥ 18 years
• With metastatic melanoma
• Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
• Having formulated a non-opposition

Exclusion criteria

• • Minor patient < 18 years
• Pregnancy or breastfeeding
• Other type of tumor than metastatic melanoma
• Non-eligibility for the examination
• Refusal of participation

Trial design

56 participants in 1 patient group

value of 4D body-to-whole dynamic acquisition in FDG

Description:

differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this "unconfirmed progression" after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma

Treatment:

Diagnostic Test: value of 4D body-to-whole dynamic acquisition in FDG